[1]
Waddington CH. The epigenotype. 1942. Int J Epidemiol 2012; 41: 10-3.
[2]
Holliday R. Epigenetics: an overview. Dev Genet 1994; 15: 453-7.
[3]
Wu C, Morris JR. Genes, genetics, and epigenetics: a correspondence. Science 2001; 293: 1103-5.
[4]
Bird A. Perceptions of epigenetics. Nature 2007; 447: 396-8.
[5]
Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009; 23: 781-3.
[6]
Deans C, Maggert KA. What do you mean, “epigenetic”? Genetics 2015; 199: 887-96.
[7]
Wei JW, Huang K, Yang C, Kang CS. Non-coding RNAs as regulators in epigenetics. (Review) Oncol Rep 2017; 37: 3-9.
[8]
Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet 2016; 17: 284-99.
[9]
Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Semin Cancer Biol 2020.
[10]
Vafadar A, Shabaninejad Z, Movahedpour A, et al. Long Non-Coding RNAs As Epigenetic Regulators in Cancer. Curr Pharm Des 2019; 25: 3563-77.
[11]
Arif KMT, Elliott EK, Haupt LM, Griffiths LR. Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets. Cancers (Basel) 2020; 12.
[12]
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-6.
[13]
Lu Y, Chan YT, Tan HY, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer 2020; 19: 79.
[14]
Aleksakhina SN, Kashyap A, Imyanitov EN. Mechanisms of acquired tumor drug resistance. Biochim Biophys Acta Rev Cancer 2019; 1872188310
[15]
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-26.
[16]
Sharma A. Hiding in Plain Sight: Epigenetic Plasticity in Drug-Induced Tumor Evolution. Epigenet Insights 2019; 122516865719870760
[17]
Lund RJ, Huhtinen K, Salmi J, et al. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer. Sci Rep 2017; 7: 1469.
[18]
Nava M, Dutta P, Farias-Eisner R, Vadgama JV, Wu Y. Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance. Sci Rep 2019; 9: 5141.
[19]
Grasse S, Lienhard M, Frese S, et al. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. Genome Med 2018; 10: 55.
[20]
Christmann M, Kaina B. Epigenetic regulation of DNA repair genes and implications for tumor therapy. Mutat Res 2019; 780: 15-28.
[21]
Dolan ME, Pegg AE. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997; 3: 837-47.
[22]
Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65: 4218-27.
[23]
Wang CH, Wu HT, Cheng HM, et al. Inhibition of glutathione S-transferase M1 by new gabosine analogues is essential for overcoming cisplatin resistance in lung cancer cells. J Med Chem 2011; 54: 8574-81.
[24]
Choi JA, Kwon H, Cho H, Chung JY, Hewitt SM, Kim JH. ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer. Cancers (Basel) 2019; 11.
[25]
Perez-Alea M, McGrail K, Sanchez-Redondo S, et al. ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment. Oncogene 2017; 36: 5695-708.
[26]
Bacolod MD, Lin SM, Johnson SP, et al. The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets 2008; 8: 172-9.
[27]
Sladek NE. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr Pharm Des 1999; 5: 607-25.
[28]
Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci 2020; 21.
[29]
Wu Y, Zhang Z, Cenciarini ME, et al. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERalpha-GREB1 Transcriptional Axis. Cancer Res 2018; 78: 671-84.
[30]
Bacolod MD, Barany F. MGMT epigenetics: the influence of gene body methylation and other insights derived from integrated methylomic, transcriptomic, and chromatin analyses in various cancer types. Curr Cancer Drug Targets 2020.
[31]
Bacolod MD, Das SK, Sokhi UK, et al. Examination of Epigenetic and other Molecular Factors Associated with mda-9/Syntenin Dysregulation in Cancer Through Integrated Analyses of Public Genomic Datasets. Adv Cancer Res 2015; 127: 49-121.
[32]
Bacolod MD, Barany F, Pilones K, Fisher PB, de Castro RJ. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumors. Adv Cancer Res 2018; 142.
[33]
Audia JE, Campbell RM. Histone Modifications and Cancer. Cold Spring Harb Perspect Biol 2016; 8a019521
[34]
Paschall AV, Yang D, Lu C, et al. H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance. J Immunol 2015; 195: 1868-82.
[35]
To KK, Tong WS, Fu LW. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. Lung Cancer 2017; 103: 58-65.
[36]
Ryu H, Jin H, Ho JN, et al. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer. Biol Pharm Bull 2019; 42: 66-72.
[37]
Nishizawa Y, Ikeda R, Yamamoto M, et al. 5-Aza-2-deoxycytidine Enhances the Sensitivity of 5-Fluorouracil by Demethylation of the Thymidine Phosphorylase Promoter. Anticancer Res 2019; 39: 4129-36.
[38]
Rathod D, Fu Y, Patel K. BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation. Eur J Pharm Sci 2019; 138105039
[39]
Lampis A, Hahne JC, Hedayat S, Valeri N. MicroRNAs as mediators of drug resistance mechanisms. Curr Opin Pharmacol 2020; 54: 44-50.
[40]
Yi D, Xu L, Wang R, Lu X, Sang J. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol Int 2019; 43: 12-21.
[41]
Li M, Gao M, Xie X, et al. MicroRNA-200c reverses drug resistance of human gastric cancer cells by targeting regulation of the NER-ERCC3/4 pathway. Oncol Lett 2019; 18: 145-52.
[42]
Li B, Jiang J, Assaraf YG, Xiao H, Chen ZS, Huang C. Surmounting cancer drug resistance: New insights from the perspective of N(6)-methyladenosine RNA modification. Drug Resist Updat 2020; 53100720
[43]
A user’s guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011; 9e1001046
[44]
Vazquez F, Boehm JS. The Cancer Dependency Map enables drug mechanism-of-action investigations. Mol Syst Biol 2020; 16e9757
[45]
Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41: D955-61.
[46]
Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-7.
[47]
Stupp R, Hegi ME, Mason WP, et al. European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
[48]
Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-oncol 2019; 21: 167-78.
[49]
Gordevicius J, Krisciunas A, Groot DE, et al. Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients. Clin Cancer Res 2018; 24: 3317-24.
[50]
Liu XR, Zhang RY, Gong H, et al. Methylome Variation Predicts Exemestane Resistance in Advanced ER(+) Breast Cancer. Technol Cancer Res Treat 2020; 191533033819896331
[51]
Isshiki Y, Melnick AM. Epigenetic mechanisms of therapy resistance in diffuse large B cell lymphoma (DLBCL). Curr Cancer Drug Targets 2020.
[52]
Wood S, Willbanks A, Cheng J. The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance. Curr Cancer Drug Targets 2020.
[53]
Culig Z. miRNA as regulators of prostate carcinogenesis and endocrine and chemoresistance. Curr Cancer Drug Targets 2020.
[54]
Rauscher S, Greil R, Geisberger R. Re-sensitizing tumor cells to cancer drugs with epigenetic regulators. Curr Cancer Drug Targets 2020.
[55]
To KKW, Cho WCS. Flavonoids overcome drug resistance to cancer chemotherapy by epigenetically modulating multiple mechanisms. Curr Cancer Drug Targets 2020.
[56]
Giardina SF, Valdambrini E, Warren JD, Barany F. PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance. Curr Cancer Drug Targets 2020.
48